Chiltern will draw upon many parts of TAHSC, including the Clinical Research Centre (CRC) which is located on the same University Medical School and hospital campus as Chiltern Early Phase and NHS Tayside’s Clinical Imaging and Interventional Centre (CIIC).
The CRC is the hub for clinical trial activity with links to additional satellite units in Tayside. Chiltern and the CRC will focus on studies in areas such as diabetes, COPD, cardiovascular disease, neurological conditions and Hepatitis C.
Glenn Kerkof, CEO of Chiltern, said: “This new partnership demonstrates Chiltern’s commitment to deliver high quality POC studies to our clients and adding value to their drug development processes by combining our extensive experience with world class academic-based research and expertise. We are proud of this new collaboration and confident that the world class Key Opinion Leaders in TAHSC will augment our expertise in our early phase business.”
Jill Belch, professor of Tayside Research and Development Director, said: “Supporting the local research community and building strong working relationships with industrial partners are key objectives for TAHSC. This agreement will allow potential access to new drugs for our patients in Tayside and allow our researchers to participate in a larger range of clinical studies.”